Last reviewed · How we verify

Aramchol free acid — Competitive Intelligence Brief

Aramchol free acid (Aramchol free acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SCD1 inhibitor. Area: Hepatology.

phase 3 SCD1 inhibitor Stearoyl-CoA desaturase 1 (SCD1) Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Aramchol free acid (Aramchol free acid) — Galmed Pharmaceuticals Ltd. Aramchol inhibits stearoyl-CoA desaturase 1 (SCD1), an enzyme that converts saturated fatty acids to monounsaturated fatty acids, thereby reducing hepatic lipogenesis and improving liver metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aramchol free acid TARGET Aramchol free acid Galmed Pharmaceuticals Ltd phase 3 SCD1 inhibitor Stearoyl-CoA desaturase 1 (SCD1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SCD1 inhibitor class)

  1. Galmed Pharmaceuticals Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aramchol free acid — Competitive Intelligence Brief. https://druglandscape.com/ci/aramchol-free-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: